Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Vet Microbiol ; 213: 102-107, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29291992

ABSTRACT

The aim of this study was to investigate the prevalence and the implicated mechanisms of resistance against selected veterinary fluoroquinolones (enrofloxacin, marbofloxacin and pradofloxacin) among 101 Pseudomonas aeruginosa (n=75) and Escherichia coli (n=26) isolates collected from dogs suffering from otitis. Resistance ranged from 32.0% to 48.0% with differences not being considered statistically significant among the three agents or between the two bacterial species. However, individual MICs of pradofloxacin, the latest veterinary fluoroquinolone, were significantly lower than those of enrofloxacin, the oldest one, indicating an increased in vitro potency of the former antimicrobial. Pradofloxacin MIC90 was, additionally, the lowest (8µg/ml), in E. coli, or among the lowest (8µg/ml), in P. aeruginosa isolates. Resistance was in most cases associated with topoisomerase substitutions, with patterns GyrA:V73G in P. aeruginosa and GyrA:S83L+D87N/ParC:S58I+A86V in E. coli being reported for the first time in small animal isolates. Only 6.7% and 15.4% of P. aeruginosa and E. coli otitis isolates, respectively, carried plasmid-mediated quinolone resistance (PMQR) genes, which, moreover, contributed minimally to resistance. Efflux pump activity was additionally detected in resistant E. coli isolates, even those lacking topoisomerase substitutions or PMQR genes. The emergence of resistance in the canine otitis isolates seemed to be associated with previous, prolonged systemic fluoroquinolone administration. In any case, antimicrobial susceptibility testing should guide the selection of systemic FQs for the treatment of canine otitis.


Subject(s)
Dog Diseases/epidemiology , Drug Resistance, Bacterial , Escherichia coli Infections/veterinary , Otitis/veterinary , Pseudomonas Infections/veterinary , Animals , Anti-Bacterial Agents/pharmacology , Dog Diseases/drug therapy , Dog Diseases/microbiology , Dogs , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Escherichia coli Infections/drug therapy , Escherichia coli Infections/epidemiology , Escherichia coli Infections/microbiology , Fluoroquinolones/pharmacology , Greece/epidemiology , Microbial Sensitivity Tests/veterinary , Otitis/drug therapy , Otitis/microbiology , Prevalence , Pseudomonas Infections/drug therapy , Pseudomonas Infections/epidemiology , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/isolation & purification
2.
Res Vet Sci ; 117: 187-195, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29291486

ABSTRACT

Knowledge of in vitro antimicrobial interactions can serve as a guide for clinical application of combination antimicrobial regimens. The aim of the present study was to determine the pharmacodynamic interactions of amikacin with either amoxicillin/clavulanic acid, ceftazidime, enrofloxacin or marbofloxacin against clinical canine Escherichia coli isolates. Bactericidal activity of individual antimicrobials was assessed by use of static kill curves. Interactions between amikacin and each of the ß-lactams or fluoroquinolones were subsequently analyzed by employing the fractional maximal effect method. Amikacin, compared with all other agents, displayed the most rapid and extensive bacterial killing, the lowest level (with respect to MIC) at which half the maximal effect was observed and the most linear concentration-effect relationship. The combinations of amikacin with amoxicillin/clavulanic acid or ceftazidime were completely synergistic in four and three out of the five investigated isolates, respectively, with additivity being sporadically observed. On the other hand, the combinations of amikacin with enrofloxacin or marbofloxacin yielded a mosaic of interaction types with no discernible pattern or differentiation between fluoroquinolone-susceptible and resistant isolates; synergy was only infrequently observed, mainly at increased fluoroquinolone concentrations. In conclusion, the combinations of amikacin with the two ß-lactams were found to be more promising, in terms of synergy achievement, compared with the respective combinations with the two fluoroquinolones.


Subject(s)
Amikacin/pharmacology , Dog Diseases/drug therapy , Escherichia coli/drug effects , Fluoroquinolones/pharmacology , beta-Lactams/pharmacology , Animals , Anti-Bacterial Agents , Dog Diseases/microbiology , Dogs , Drug Therapy, Combination , Escherichia coli/isolation & purification , Escherichia coli Infections/drug therapy , Escherichia coli Infections/veterinary , Microbial Sensitivity Tests
3.
Ticks Tick Borne Dis ; 8(3): 341-346, 2017 03.
Article in English | MEDLINE | ID: mdl-28089651

ABSTRACT

Canine tick-borne pathogens such as Ehrlichia canis and Hepatozoon canis are widespread in the Mediterranean basin but have never been reported or investigated in Cyprus. We describe herein the presence of canine tick-borne pathogens in three dogs with clinical signs compatible with vector-borne diseases from Paphos area of Cyprus. Molecular and phylogenetic analysis revealed the presence of E. canis, Anaplasma platys, H. canis, Babesia vogeli and Mycoplasma haemocanis in Cyprus. One dog co-infected with E. canis, H. canis, B. vogeli and M. haemocanis is, to the best of our knowledge, the first report of this multiple co-infection in dogs. The tick-borne pathogens reported in the current study should be considered in the differential diagnoses in dogs exposed to ticks in Cyprus.


Subject(s)
Coinfection/veterinary , Dog Diseases , Tick-Borne Diseases/veterinary , Anaplasma/genetics , Anaplasma/pathogenicity , Animals , Babesiosis/diagnosis , Babesiosis/epidemiology , Babesiosis/parasitology , Coccidia/genetics , Coccidia/pathogenicity , Coccidiosis/diagnosis , Coccidiosis/epidemiology , Coccidiosis/parasitology , Coccidiosis/veterinary , Coinfection/epidemiology , Coinfection/microbiology , Coinfection/parasitology , Cyprus/epidemiology , Diagnosis, Differential , Dog Diseases/diagnosis , Dog Diseases/epidemiology , Dog Diseases/microbiology , Dog Diseases/parasitology , Dogs , Ehrlichia canis/genetics , Ehrlichia canis/pathogenicity , Ehrlichiosis/diagnosis , Ehrlichiosis/epidemiology , Ehrlichiosis/microbiology , Ehrlichiosis/veterinary , Mycoplasma/genetics , Mycoplasma/pathogenicity , Mycoplasma Infections/diagnosis , Mycoplasma Infections/epidemiology , Mycoplasma Infections/parasitology , Mycoplasma Infections/veterinary , Phylogeny , Polymerase Chain Reaction , Tick-Borne Diseases/epidemiology , Tick-Borne Diseases/microbiology , Tick-Borne Diseases/parasitology , Ticks/microbiology , Ticks/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...